Monte Rosa Therapeutics (GLUE) Stock Price, News & Analysis

Company Overview

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $4.14 to $4.27
• 50-Day Range: $4.14 to $5.96
• 52-Week Range: $3.50 to $12.40
• Volume: 52,930 shs
• Average Volume: 610,900 shs
• Market Capitalization: $255.27 million
• P/E Ratio: 51.88
• Dividend Yield: N/A
• Price Target: $15.33
• Consensus Rating: Moderate Buy

Monte Rosa Therapeutics Stock Analysis - MarketRank™

Monte Rosa Therapeutics scored higher than 37% of companies evaluated by MarketBeat, and ranked 817th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Monte Rosa Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Monte Rosa Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Monte Rosa Therapeutics are expected to grow in the coming year, from ($1.49) to ($1.41) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Monte Rosa Therapeutics is 52.88, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.86.

Price to Earnings Ratio vs. Sector

The P/E ratio of Monte Rosa Therapeutics is 52.88, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.93.

Price to Book Value per Share Ratio

Monte Rosa Therapeutics has a P/B Ratio of 1.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.40% of the float of Monte Rosa Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Monte Rosa Therapeutics has a short interest ratio ("days to cover") of 20.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Monte Rosa Therapeutics has recently increased by 0.68%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Monte Rosa Therapeutics does not currently pay a dividend.

Dividend Growth

Monte Rosa Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

19.40% of the float of Monte Rosa Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Monte Rosa Therapeutics has a short interest ratio ("days to cover") of 20.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Monte Rosa Therapeutics has recently increased by 0.68%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.50

News Sentiment

Monte Rosa Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Monte Rosa Therapeutics this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for GLUE on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Monte Rosa Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.90% of the stock of Monte Rosa Therapeutics is held by insiders.

Percentage Held by Institutions

79.96% of the stock of Monte Rosa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GLUE Stock Analysis - Frequently Asked Questions

How have GLUE shares performed this year?

Monte Rosa Therapeutics' stock was trading at $6.94 at the beginning of 2025. Since then, GLUE shares have decreased by 39.0% and is now trading at $4.23.

How were Monte Rosa Therapeutics' earnings last quarter?

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) announced its quarterly earnings results on Thursday, August, 7th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.16. The company had revenue of $23.19 million for the quarter, compared to analysts' expectations of $7.23 million. Monte Rosa Therapeutics had a net margin of 3.86% and a trailing twelve-month return on equity of 2.65%.

When did Monte Rosa Therapeutics IPO?

Monte Rosa Therapeutics (GLUE) raised $211 million in an initial public offering (IPO) on Thursday, June 24th 2021. The company issued 11,700,000 shares at $17.00-$19.00 per share.

Who are Monte Rosa Therapeutics' major shareholders?

Top institutional investors of Monte Rosa Therapeutics include CWM LLC (0.05%), Wealth Enhancement Advisory Services LLC (0.03%), Los Angeles Capital Management LLC (0.03%) and Pallas Capital Advisors LLC (0.02%). Insiders that own company stock include Versant Venture Capital Vi, L, Edmund Dunn and Chandra P Leo.
View institutional ownership trends.

How do I buy shares of Monte Rosa Therapeutics?

Shares of GLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Monte Rosa Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Monte Rosa Therapeutics investors own include AU Optronics (AUOTY), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Today: 8/08/2025
• Last Earnings: 8/14/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GLUE
• CIK: 1826457
• Web: www.monterosatx.com
• Phone: 617-949-2643
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Monte Rosa Therapeutics: $15.33
• High Price Target: $19.00
• Low Price Target: $10.00
• Potential Upside/Downside: +262.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.08
• Trailing P/E Ratio: 52.88
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$72.70 million
• Net Margins: 3.86%
• Pretax Margin: 5.93%
• Return on Equity: 2.65%
• Return on Assets: 1.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.61
• Quick Ratio: 5.61

Sales & Book Value

• Annual Sales: $159.49 million
• Price / Sales: 1.63
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.63 per share
• Price / Book: 1.17

Miscellaneous

• Outstanding Shares: 61,510,000
• Free Float: 57,266,000
• Market Cap: $260.19 million
• Optionable: Optionable
• Beta: 1.42